metronidazole has been researched along with Hepatic Encephalopathy in 14 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encephalopathy is a disorder characterized by altered brain function, which can be attributed to various causes." | 5.37 | Metronidazole-induced encephalopathy in a patient with liver cirrhosis. ( Cheong, HC; Cho, EY; Cho, YB; Jeong, TG; Kim, HC; Kim, TH; Yang, BJ, 2011) |
| "001) and the elimination half-life prolonged (20 +/- 9 versus 7." | 5.27 | Metronidazole pharmacokinetics in patients with hepatic encephalopathy. ( Andreasen, PB; Døssing, M; Loft, S; Sonne, J, 1987) |
| "In cirrhotic patients with advanced hepatic encephalopathy treatment with LOLA was safe and associated with relatively rapid improvement and shorter hospital stay." | 2.76 | Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. ( Abbas, Z; Abid, S; Hamid, S; Islam, M; Jafri, W; Mumtaz, K; Shah, HA, 2011) |
| "To review the management of hepatic encephalopathy (HE), including lifestyle modifying strategies and pharmacological interventions." | 2.53 | Management of Hepatic Encephalopathy: A Primer. ( Bridgeman, MB; Dixit, D; Jawaro, T; Yang, A, 2016) |
| "Hepatic encephalopathy is characterized by neuropsychiatric abnormalities in patients with liver failure." | 2.45 | Hepatic encephalopathy: pathophysiology and emerging therapies. ( Shaikh, OS; Sundaram, V, 2009) |
| "Encephalopathy is a disorder characterized by altered brain function, which can be attributed to various causes." | 1.37 | Metronidazole-induced encephalopathy in a patient with liver cirrhosis. ( Cheong, HC; Cho, EY; Cho, YB; Jeong, TG; Kim, HC; Kim, TH; Yang, BJ, 2011) |
| "001) and the elimination half-life prolonged (20 +/- 9 versus 7." | 1.27 | Metronidazole pharmacokinetics in patients with hepatic encephalopathy. ( Andreasen, PB; Døssing, M; Loft, S; Sonne, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mekky, MA | 1 |
| Riad, AR | 1 |
| Gaber, MA | 1 |
| Abdel-Malek, MO | 1 |
| Swifee, YM | 1 |
| Leise, MD | 1 |
| Poterucha, JJ | 1 |
| Kamath, PS | 1 |
| Kim, WR | 1 |
| Jawaro, T | 1 |
| Yang, A | 1 |
| Dixit, D | 1 |
| Bridgeman, MB | 1 |
| Sundaram, V | 1 |
| Shaikh, OS | 1 |
| Sharma, P | 1 |
| Eesa, M | 1 |
| Scott, JN | 1 |
| Cheong, HC | 1 |
| Jeong, TG | 1 |
| Cho, YB | 1 |
| Yang, BJ | 1 |
| Kim, TH | 1 |
| Kim, HC | 1 |
| Cho, EY | 1 |
| Abid, S | 1 |
| Jafri, W | 1 |
| Mumtaz, K | 1 |
| Islam, M | 1 |
| Abbas, Z | 1 |
| Shah, HA | 1 |
| Hamid, S | 1 |
| Fehérvári, I | 1 |
| Nemes, B | 1 |
| Görög, D | 1 |
| Gerlei, Z | 1 |
| Kóbori, L | 1 |
| Deenadayalu, VP | 1 |
| Orinion, EJ | 1 |
| Chalasani, NP | 1 |
| Yoo, HY | 1 |
| Crossley, IR | 1 |
| Williams, R | 1 |
| Morgan, MH | 1 |
| Read, AE | 1 |
| Speller, DC | 1 |
| Uhl, MD | 1 |
| Riely, CA | 1 |
| Alexander, T | 1 |
| Thomas, K | 1 |
| Cherian, AM | 1 |
| Loft, S | 1 |
| Sonne, J | 1 |
| Døssing, M | 1 |
| Andreasen, PB | 1 |
6 reviews available for metronidazole and Hepatic Encephalopathy
| Article | Year |
|---|---|
Management of hepatic encephalopathy in the hospital.
Topics: Disease Management; Drug Therapy, Combination; Gastrointestinal Agents; Hepatic Encephalopathy; Huma | 2014 |
Management of Hepatic Encephalopathy: A Primer.
Topics: Anti-Bacterial Agents; Disaccharides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Metronidazole | 2016 |
Hepatic encephalopathy: pathophysiology and emerging therapies.
Topics: Ammonia; Anti-Infective Agents; Drug Therapy, Combination; Dyskinesias; Gastrointestinal Agents; Hep | 2009 |
Toxic and acquired metabolic encephalopathies: MRI appearance.
Topics: Brain Diseases, Metabolic; Carbon Monoxide Poisoning; Cocaine; Cyclosporine; Diagnosis, Differential | 2009 |
[Hepatic encephalopathy and liver transplantation].
Topics: Ammonia; Anti-Infective Agents; Colon; Dipeptides; Disaccharides; End Stage Liver Disease; Evidence- | 2012 |
Progress in the treatment of chronic portasystemic encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Bromocriptine; Chronic Disease; Clinical Trials as To | 1984 |
4 trials available for metronidazole and Hepatic Encephalopathy
| Article | Year |
|---|---|
Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
Topics: Acute Disease; Adult; Ammonia; Anti-Infective Agents; Female; Hepatic Encephalopathy; Humans; Length | 2018 |
Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Topics: Anti-Infective Agents; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up | 2011 |
Progress in the treatment of chronic portasystemic encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Animals; Bromocriptine; Chronic Disease; Clinical Trials as To | 1984 |
Treatment of hepatic encephalopathy with metronidazole.
Topics: Aged; Ammonia; Clinical Trials as Topic; Double-Blind Method; Electroencephalography; Female; Hepati | 1982 |
5 other studies available for metronidazole and Hepatic Encephalopathy
| Article | Year |
|---|---|
Metronidazole-induced encephalopathy in a patient with liver cirrhosis.
Topics: Anti-Infective Agents; Brain Diseases; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Magnetic Res | 2011 |
Abnormal enhancing lesion of dentate nuclei causing neurologic symptoms induced by metronidazole toxicity.
Topics: Anti-Infective Agents; Cerebellar Nuclei; Hepatic Encephalopathy; Humans; Magnetic Resonance Imaging | 2005 |
Metronidazole in treating portosystemic encephalopathy.
Topics: Aged; Female; Hepatic Encephalopathy; Humans; Metronidazole; Substance-Related Disorders | 1996 |
Effect of three antibacterial drugs in lowering blood & stool ammonia production in hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Ampicillin; Feces; Hepatic Encephalopathy; Humans; Hydrogen-Ion Conce | 1992 |
Metronidazole pharmacokinetics in patients with hepatic encephalopathy.
Topics: Aged; Female; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Kinetics; Male; Metronidazole; | 1987 |